<unk>  SA is a company specialized in the development of ultra-rapid in vitro diagnostic tests, located in Lausanne, Switzerland.<unk>  has developed the abioSCOPE, a point-of-care diagnostic platform using its patented nanofluidic technology. The abioSCOPE is implemented in intensive care units and emergency departments to enable early identification of sepsis using a proprietary biomarker, Pancreatic Stone Protein (PSP). Secreted mainly by the pancreas and stomach, PSP rises rapidly in the blood in case of sepsis development and up to 72 hours before today's standard of care. Thus, this is a good and sensitive warning signal to guide doctors in their decision to start antibiotic treatment. Besides the diagnostic value of PSP for sepsis, its availability at the bedside and the availability of the result in 5 minutes provides an additional opportunity to closely monitor patients at risk of developing sepsis. The abioSCOPE is also used in primary care for the screening of iron deficiency, respiratory allergies and more recently for COVID-19 screening with an antigenic saliva and nasopharyngeal test.
Abionic
Endemic 
Toxoid
Sense
Grief
Heteromer
Depurative
Tocolytic